Inactivated Orf Virus Shows Antifibrotic Activity and Inhibits Human Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Replication in Preclinical Models

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Paulsen, Daniela ^a   Urban, Andreas ^a   Knorr, Andreas ^b   Hirth Dietrich, Claudia ^b   Siegling, Angela ^b,i   Volk, Hans Dieter ^c,h   Mercer, Andrew A ^d   Limmer, Andreas ^e   Schumak, Beatrix ^f   Knolle, Percy ^e,g   Ruebsamen Schaeff, Helga ^a   Weber, Olaf ^b  

^a AiCuris GmbH   (Germany)

^b BAYER PHARMA AG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f UNIVERSITY OF BONN   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ Intellectual Property Management   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; INACTIVATED ORF VIRUS; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PLACEBO; UNCLASSIFIED DRUG; VIROTHERAPY AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSS PRESENTATION; DISEASE MODEL; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG POTENCY; ENDOTHELIUM CELL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; IN VITRO STUDY; IN VIVO STUDY; LIVER FIBROSIS; LIVER INJURY; LIVER SINUSOID; MALE; MOUSE; NONHUMAN; PARAPOXVIRUS OVIS; POXVIRUS; STRAIN DIFFERENCE; TRANSGENIC MOUSE; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TITRATION;

ANIMALS; HEPACIVIRUS; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS; MALE; MICE; ORF VIRUS; RATS; SWINE;

EID: 84884169913     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074605     Document Type: Article

References (51)

1. WHO: HCV. Fact Sheet N° 165.
2. Kane M, (1995) Global programme for control of hepatitis B infection. Vaccine 13: S47-S49.
3. Davis GL, Albright JE, Cook SF, Rosenberg DM, (2003) Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 9: 331-338.
4. Thein HH, Yi Q, Dore GJ, Krahn MD, (2008) Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 48: 418-431.
5. Nature Outlook Hepatitis C, (2011) Nature. 474: S1-S21.
6. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, et al. (2006) German HEP-NET Acute HCV Study Group Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 43: 250-256.
7. Lange CM, Zeuzem S (2012) Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol Oct 24. pii: S0168-8278(12)00818-5. doi:10.1016/j.jhep.2012.10.019. [Epub ahead of print].
8. Haig DM, Mercer AA, (1989) Orf. Vet Res 29: 311-326.
9. Fleming SB, McCaughan CA, Andrews AE, Nash AD, Mercer AA, (1997) A homolog of interleukin-10 is encoded by the poxvirus orf virus. J Virol 71: 4857-4861.
10. Haig DM, McInnes CJ, Thomson J, Wood A, Bunyan K, et al. (1998) The orf virus OV20.0L gene product is involved in interferon resistance and inhibits an interferon-inducible, double-stranded RNA-dependent kinase. Immunology 93: 335-340.
11. Weber O, Siegling A, Friebe A, Limmer A, Schlapp T, et al. (2003) Inactivated Parapoxvirus ovis (Orf virus) has antiviral activity against hepatitis B virus and herpes simplex virus. J Gen Virol 84: 1843-1852.
12. Nowatzky J, Knorr A, Hirth-Dietrich C, Siegling A, Volk H-D, et al. (2012) Inactivated Orf virus (Parapoxvirus ovis) elicits antifibrotic activity in models of liver fibrosis. Hepatol Res Sep 13. doi:10.1111/j.1872-034X.2012.01086.x. [Epub ahead of print].
13. Büttner M, Czerny CP, Lehner KH, Wertz K, (1995) Interferon induction in peripheral blood mononuclear leukocytes of man and farm animals by poxvirus vector candidates and some poxvirus constructs. Vet Immunol Immunopathol 46: 237-250.
14. Lohmann V, Körner F, Koch JO, Herian U, Theilmann L, et al. (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110-113.
15. Krieger, N Krieger N, Lohmann V, Bartenschlager R, (2001) Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 75: 4614-4624.
16. O'Boyle DR 2nd, Nower PT, Lemm JA, Valera L, Sun JH, et al. (2005) Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. Antimicrob Agents Chemother 49: 1346-1353.
17. Pohlscheidt M, Langer U, Minuth T, Bödeker B, Apeler H, et al. (2008) Development and optimization of a procedure for the production of parapoxvirus ovis by large-scale microcarrier cell culture in a non-animal, non-human and non-plant-derived medium. Vaccine 26: 1552-1565.
18. Chromczynski P, Sacchi N, (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-Phenolchloroform extraction. Anal. Biochem 162: 156-159.
19. Weber O, Schlemmer KH, Hartmann E, Hagelschuer I, Paessens A, et al. (2002) Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res 54: 69-75.
20. Wingender G, Garbi N, Schumak B, Jüngerkes F, Endl E, et al. (2006) Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol. 36: 12-20.
21. Bhunchet E, Wake K, (1992) Role of mesenchymal cell populations in porcine serum-induced rat liver fibrosis. Hepatology 16: 1452-1473.
22. Limmer A, Ohl J, Kurts C, Ljunggren HG, Reiss Y, et al. (2000) Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med. 6 (12): 1348-1354.
23. Shastri N, Gonzalez F, (1993) Endogenous generation and presentation of the ovalbumin peptide/Kb complex to T cells. J Immunol 150: 2724-2736.
24. Bataller R, Brenner DA, (2005) Liver fibrosis. J Clin Invest 115: 209-218.
25. Hernandez-Gea V, Friedman SL, (2011) Pathogenesis of liver fibrosis. Annu Rev Pathol 6: 425-456.
26. Weber O, Mercer AA, Friebe A, Knolle P, Volk H-D (2012) Therapeutic immunomodulation using a virus-the potential of inactivated orf virus. Eur J Clin Microbiol Infect Dis DOI 10.1007/s10096-012-1780-x, published online on Nov 22, ahead of print.
27. Friebe A, Siegling A, Friederichs S, Volk HD, Weber O, (2004) Immunomodulatory effects of inactivated Parapoxvirus ovis (ORF virus) on human peripheral immune cells: inductionof cytokine secretion in monocytes and Th1-like cells. J Virol 78: 9400-9411.
28. Joffre OP, Segura E, Savina A, Amigorena S (2012) Cross-presentation by dendritic cells. Nature Rev Immunol 12, 557-569.
29. Burgdorf S, Schölz C, Kautz A, Tampé R, Kurts C (2008) Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation Nat. Immunol 9, 558-566.
30. Kern M, Popov A, Scholz K, Schumak B, Djandjl D, et al. (2010) Virally Infected Mouse Liver Endothelial Cells Trigger CD8+ T-Cell Immunity. Gastroenterol 138: 336-346.
31. Heikenwalder M, Polymendou M, Junt T, Sigurdson C, Wagner H, et al. (2004) Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med. 10 (2): 187-192.
32. Bauer S, (2013) Toll-like receptor 9 processing: the key event in toll-like recptor 9 activation? Immunol Lett. 149 (1-2): 86-87.
33. Siegemund S, Hartl A, von Buttlar H, Dautel F, Raue R, et al. (2009) Conventional bone marrow-derived dendritic cells contribute to toll-like receptor-independent production of alpha/beta interferon in response to inactivated parapoxvirus ovis. J Virol. 83: 9411-9422.
34. Kruse N, Weber O, (2001) Selective induction of apoptosis in antigen-presenting cells in mice by parapoxvirus ovis. J Virol 75: 4699-4704.
35. Matsuhita T, Ando K, Kimura K, Ohnishi H, Imawari M, et al. (1999) IL-12 induces specific cytotoxicity against regenerating hepatocytes in vivo. Intern Immunology 11 (5): 657-665.
36. Trobonjaca Z, Kröger A, Stober D, Leithäuser F, Möller P, et al. (2012) Activating immunity in the liver. II. IFN b attenuates NK cell-dependent liver injury triggered by liver NKT cell activation. J Immunol 168: 3763-3770.
37. Wohlleber D, Kashkar H, Gärtner K, Frings MK, Odenthal M, et al. (2012) TNF-induced target cell killing by CTL activated through cross-presentation. Cell Rep 2: 478-487.
38. Mercer AA, Ueda N, Friederichs S-M, Hofmann K, Fraser KM, et al. (2006) Comparative analysis of genome sequences of three isolates of Orf virus reveals unexpected sequence variation. Virus Research 116: 146-158.
39. Robinson AJ, Ellis G, Balassu T, (1982) The genome of orf virus: restriction endonuclease analysis of viral DNA isolated from lesions of orf in sheep. Arch Virol 71: 43-55.
40. McGuire MJ, Johnston SA, Sykes KF, (2012) Novel immune-modulator identified by a rapid, functional screen of the parapoxvirus ovis (Orf virus) genome. Proteome Sci. Jan 13 10(1): 4 doi:10.1186/1477-5956-10-4.
41. Cottone R, Büttner M, Bauer B, Henkel M, Hettich E, et al. (1998) Analysis of genomic rearrangement and subsequent gene deletion of the attenuated Orf virus strain D1701 Virus Res. 56: 53-67.
42. Parrish S, Moss B, (2006) Characterization of a vaccinia virus mutant with a deletion of the D10R gene encoding a putative negative regulator of gene expression. J Virol 80: 553-61.
43. Lin C-L, Chung C-S, Heine HG, Wen C, (2000) Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo J Virol. 74: 3353-3365.
44. Friebe A, Friederichs S, Scholz K, Janssen U, Scholz C, et al. (2011) Characterization of immunostimulatory components of Orf virus (parapoxvirus ovis). J Gen Virol 92: 1571-1584.
45. Baroni GS, Dambrosio L, Curto P, Casini A, Mancini R, et al. (1996) Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 23: 1189-1199.
46. Rockey DC, MaherJJ, Jamagin WR, Gabbiani G, Friedman SL, (1992) Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma. Hepatology 16: 776-784.
47. Weng H, Mertens P, Gressner A, Dooley S, (2007) IFN-γ abrogates profibrotic TGF-ß signaling in liver by targeting expression of inhibitory and receptor Smads. J Hepatol 46: 295-303.
48. Gurujeyalakshmi G, Giri SN, (1995) Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Experimental Lung Research 21: 791-808.
49. Shi MN, Zheng WD, Zhan LJ, Chen ZX, Wang XZ, (2005) Effect of IL-10 on the expression of HSC growth factors in hepatic fibrosis rats World J Gastroenterol. 31: 4788-4793.
50. Shi MN, Huang YH, Zheng WD, Zhang LJ, Chen ZX, et al. (2006) Relationship between transforming growth factor beta1 and anti-fibrotic effect of interleukin-10. World J Gastroenterol 15: 2357-2362.
51. Wang SC, Ohata M, Schrum L, Rippe RA, Tsukamoto H, (1998) Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells. J Biol Chem 273: 302-308.